help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Originally published online as doi:10.2353/ajpath.2008.080096 on August 7, 2008

Published online before print August 7, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Material
Right arrow All Versions of this Article:
ajpath.2008.080096v1
173/3/856    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connolly, E.
Right arrow Articles by Rogler, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connolly, E.
Right arrow Articles by Rogler, C. E.
(American Journal of Pathology. 2008;173:856-864.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.080096

Elevated Expression of the miR-17–92 Polycistron and miR-21 in Hepadnavirus-Associated Hepatocellular Carcinoma Contributes to the Malignant Phenotype

Erin Connolly*, Margherita Melegari*, Pablo Landgraf{dagger}, Tatyana Tchaikovskaya*, Bud C. Tennant{ddagger}, Betty L. Slagle§, Leslie E. Rogler*, Mihaela Zavolan, Thomas Tuschl{dagger} and Charles E. Rogler*

From the Marion Bessin Liver Research Center,* Department of Medicine, Albert Einstein College of Medicine, Bronx, NY; Laboratory of RNA Biology,{dagger} Rockefeller University, New York, NY; Department of Animal Science,{ddagger} Cornell University College of Veterinary Medicine, Ithaca, NY; Department of Molecular Virology and Microbiology,§ Baylor College of Medicine, Houston, Texas; Biozentrum, University of Basel, Switzerland and Swiss Institute of Bioinformatics, Lausanne, Switzerland

Alterations in microRNA (miRNA) expression in both human and animal models have been linked to many forms of cancer. Such miRNAs, which act directly as repressors of gene expression, have been found to frequently reside in fragile sites and genomic regions associated with cancer. This study describes a miRNA signature for human primary hepatitis B virus-positive human hepatocellular carcinoma. Moreover, two known oncomiRs—miRNAs with known roles in cancer—the miR-17–92 polycistron and miR-21, exhibited increased expression in 100% of primary human and woodchuck hepatocellular carcinomas surveyed. To determine the importance of these miRNAs in tumorigenesis, an in vitro antisense oligonucleotide knockdown model was evaluated for its ability to reverse the malignant phenotype. Both in human and woodchuck HCC cell lines, separate treatments with antisense oligonucleotides specific for either the miR-17–92 polycistron (all six members) or miR-21 caused a 50% reduction in both hepatocyte proliferation and anchorage-independent growth. The combination of assays presented here supports a role for these miRNAs in the maintenance of the malignant transformation of hepatocytes.





This article has been cited by other articles:


Home page
Mol Hum ReprodHome page
Q. Pan, X. Luo, and N. Chegini
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells
Mol. Hum. Reprod., March 1, 2010; 16(3): 215 - 227.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Raponi, L. Dossey, T. Jatkoe, X. Wu, G. Chen, H. Fan, and D. G. Beer
MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer
Cancer Res., July 15, 2009; 69(14): 5776 - 5783.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.